Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
**media[1044216]**PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to TGA registration provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapyAMSTERDAM, May 6, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company is pleased to announce that PEDMARQSI® (sodium thiosulfate anhydrous) has been registered by the Australian Therapeutic Goods Administration (TGA) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
